OSI-930 is primarily utilized in the field of oncology as a targeted therapy agent. It functions as an inhibitor of multiple receptor tyrosine kinases, including KIT, VEGFR, and PDGFR, which are often implicated in the growth and proliferation of certain cancers. By blocking these signaling pathways, OSI-930 helps to inhibit tumor angiogenesis and cancer cell survival. It has been investigated in preclinical and clinical studies for its potential in treating solid tumors, such as gastrointestinal stromal tumors (GIST) and renal cell carcinoma. Additionally, its ability to target multiple kinases makes it a candidate for combination therapies, enhancing the efficacy of other anticancer treatments. Research continues to explore its full therapeutic potential and optimal use in cancer treatment regimens.